Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response.

ABSTRACT:

Unlabelled

In registration trials, triple therapy with telaprevir (TVR), pegylated interferon (Peg-IFN), and ribavirin (RBV) achieved sustained virological response (SVR) rates between 64% and 75%, but the clinical effectiveness and economic burdens of this treatment in real-world practice remain to be determined. Records of 147 patients who initiated TVR-based triple therapy at the Mount Sinai Medical Center (May-December 2011) were reviewed. Direct medical costs for pretreatment, on-treatment, and posttreatment care were calculated using data from Medicare reimbursement databases, RED Book, and the Healthcare Cost and Utilization Project database. Costs are presented in 2012 U.S. dollars. SVR (undetectable hepatitis C virus [HCV] RNA 24 weeks after the end of treatment) was deter

SUBMITTER: Bichoupan K 

PROVIDER: S-EPMC4190678 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature